301. 黄斑ジストロフィー
[臨床試験数:41,薬物数:47(DrugBank:12),標的遺伝子数:12,標的パスウェイ数:66]
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-023111-34-FR (EUCTR) | 18/07/2011 | 08/03/2012 | A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. | A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. | Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. | Product Name: StarGen Product Code: Lentiviral vector containing ABCA4 gene INN or Proposed INN: StarGen | Oxford BioMedica (UK) Ltd | NULL | Not Recruiting | Female: yes Male: yes | 28 | Phase 1;Phase 2 | France;Netherlands;Italy |